Table 4 |
||||
|
Associations between digoxin treatment and incident breast cancer |
||||
| Exposure categories |
Cases (n = 5,565) |
Controls (n = 55,650) |
Unadjusted OR (95% CI) |
Adjusteda OR (95% CI) |
|
|
||||
| Ever/never prescribed digoxin: |
||||
| Ever user |
324 |
2,546 |
1.29 (1.14 to 1.45) |
1.30 (1.14 to 1.48) |
| Never user |
5,241 |
53,104 |
1.0 (Ref) |
1.0 (Ref) |
| Duration of digoxin therapy:b |
||||
| 7 to 18 years |
93 |
694 |
1.35 (1.10 to 1.69) |
1.39 (1.10 to 1.74) |
| 4 to 6 years |
103 |
811 |
1.29 (1.05 to 1.58) |
1.30 (1.05 to 1.61) |
| 1 to 3 years |
128 |
1,041 |
1.25 (1.03 to 1.50) |
1.25 (1.03 to 1.52) |
| Never user |
5,241 |
53,104 |
1.0 (Ref) |
1.0 (Ref) |
| Ever/never prescribed digoxin (alternate reference group): |
(n = 732) |
(n = 7,086) |
||
| Ever user |
324 |
2,546 |
1.42 (1.21 to 1.65) |
1.42 (1.14 to 1.77) |
| Never userc |
408 |
4,540 |
1.0 (Ref) |
1.0 (Ref) |
|
|
||||
|
aAdjusted for age (continuous), county of residence (categorical), and past receipt of hormone replacement therapy, anticoagulants, high- and low-dose aspirin, and non-steroidal anti-inflammatory drugs (NSAIDs) (ever/never); byears elapsed between first digoxin prescription and index date (approximate tertiles of the distribution); cthe alternate reference group is additionally defined by a history of myocardial infarction, peripheral vascular disease, cerebrovascular disease, or any combination thereof. See text for rationale. CI, confidence interval; OR, odds ratio. |
||||
|
Ahern et al. Breast Cancer Research 2008 10:R102 doi:10.1186/bcr2205 |
||||
